Related Experiment Video
Updated: Sep 9, 2025
07:47
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.6K
TMED10 expression in human cutaneous malignant melanoma
Tiziana Annese1, Daniela Coltrini2, Mirella Belleri2
1Department of Medicine and Surgery, LUM University, Casamassima, Bari, Italy.
Pathology, Research and Practice
|August 30, 2025
Summary
TMED10 protein is upregulated in cutaneous malignant melanoma (cMM), correlating with advanced tumor characteristics and poorer survival. This suggests TMED10 may promote melanoma progression and could be a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- TMED10 is implicated in protein secretion and trafficking.
- Its role in human cutaneous melanoma (cMM) remains unexplored.
- TMED10 may have dual roles in tumorigenesis.
Purpose of the Study:
- To investigate TMED10 expression in benign and malignant human melanocytic tumors.
- To determine the correlation of TMED10 with melanoma progression and clinical features.
Main Methods:
- In silico analysis of TMED10 gene expression in normal skin versus cMM.
- Immunohistochemistry and digital morphometry of TMED10 protein in 60 human samples.
- Analysis of TMED10 expression relative to Clark level, Breslow T category, BRAF mutation, and patient survival.
Main Results:
- TMED10 is upregulated in cMM compared to normal skin.
- Higher TMED10 expression correlates with increased Clark level, BRAFV600E mutation, and reduced patient survival.
- TMED10 protein levels increase with Breslow T category in tumor cells and neovasculature.
Conclusions:
- TMED10 exhibits a pro-tumorigenic function in human cMM.
- TMED10 may contribute to melanoma progression, neovascularization, and immune evasion.
- TMED10 represents a potential therapeutic target for cMM.
